User:Knowledgejwl/Cambridge Antibody Technology

Cambridge Antibody Technology, or CAT, is the UK biotechnology company whose success was based mainly on it's ability to generate antibody therapeutics, primarily using phage display phage display, and the subsequent ribosome display ribosome display, technology.

The technology developed by CAT was used to create adalimumab, the pharmaceutical industry's first fully human antibody blockbuster drug. HUMIRA, the brand name of adalimumab, is an anti-TNF antibody discovered by CAT as D2E7, then developed in the clinic and marketed by Abbott Laboratories.

Formed in 1989, CAT was acquired by Astrazeneca in 2006 for £702m, who subsequently purchased MedImmune LLC , and merged the two together to create a new global biologics arm under the name MedImmune, whose Cambridge, UK operations conduct business as MedImmune Limited.

CAT was recognised as the jewel in the crown of the british biotechnology industry and during the latter years of its existence was subject to much acquisition speculation.

Operations Products Financial Patents and legal Deals and acquisitions Employees and management Technology and publications Publicity, marketing and awards